自身免疫性胃炎根除幽门螺杆菌后的相关研究

目的探讨自身免疫性胃炎根除幽门螺杆菌(Hp)后对血清壁细胞抗体(PCA)、血清胃泌素、血清维生素B12、胃内pH值的影响。方法 104例患者均经胃镜及血清壁细胞抗体(PCA)诊断为自身免疫性胃炎(AIG),Hp感染由13C尿素呼气试验或快速尿素酶试验检查证实。患者随机分为两组:治疗组54例,对照组50例。治疗组采用经典根除幽门螺杆菌方案,共服药10d。治疗结束后4～8周,检测Hp根除情况。对照组不用任何对Hp有影响的药物,且与治疗组在同一时间作Hp检测、胃镜及PCA、血清胃泌素、血清维生素B12等检查。结果治疗组Hp根除率为83.8%,对照组根除率为0%(χ2=76.2,P<0.01),在患者根除Hp后PCA阳性率下降,转阴率为72.2%,对照组PCA转阴率为0%(χ2=57.3,P<0.01),具有统计学意义。治疗组治疗与对照组比较自身免疫性胃炎根除Hp后,PCA阳性率明显下降,血清胃泌素降低,胃内pH值及血清维生素B12升高(P<0.01),均具有统计学意义。治疗组上腹部胀痛症状改善明显,对照组中原有上腹部胀痛症状无改善,治疗组贫血明显改善,对照组贫血改善不明显。结论自身免疫性胃炎根除Hp后,PCA阳性率下降,血清胃泌素降低,胃内pH值及血清维生素B12升高。对于Hp感染的自身免疫性胃炎建议根除Hp。     

GVS-111 may be neuroprotective

The future for oral glycoprotein (GP) IIb/IIIa receptor antagonists looks uncertain following the release of disappointing results from the first large trials of these drugs at the 48th Annual Scientific Session of the American College of Cardiology [ New Orleans, US; March 1999 ]. GP IIb/IIIa receptor antagonists are considered to be the most potent antiplatelet drugs available to date. However, these agents are currently only available in IV form, and underlying cardiac events are said to continue after termination of treatment. Therefore, development of orally active GP IIb/IIIa receptor antagonists would allow administration for a longer period of time, making them more suitable for long-term prevention of coronary thrombosis.